ORIGINAL RESEARCH ARTICLE
C eramides are members of the sphingolipid family and precursors of complex sphingolipids. Since the early 1990s, studies in cultured cells and animal models have shown that the aberrant accumulation of ceramides may lead to the activation of several signaling and putative targets that impair normal cellular function, including insulin action. 1 Meanwhile, this evidence has also linked excess de novo ceramide biosynthesis to cellular stress stimuli, especially to the exposure to saturated free fatty acids (FFAs). [1] [2] [3] Ceramide and its metabolites have thus been proposed as an intermediate link between overnutrition and certain underlying abnormalities driving cardiometabolic disease risk, including insulin resistance and low-grade inflammation. [2] [3] [4] However, existing evidence relating ceramides to health outcomes comes mostly from in vitro experiments and animal studies, and it is mainly based on intermediate outcomes of cardiovascular risk. No studies have prospectively investigated the association between ceramides and the incidence of hard cardiovascular disease (CVD) end points (eg, coronary heart disease [CHD] and stroke) in a primary prevention setting. Recently, Laaksonen et al 5 reported divergent associations of distinct plasma ceramides with CVD death and proposed the ratio of 2 ceramides as the strongest predictor of CVD death among patients with stable CHD using a case-control study design.
Modification of overall dietary patterns, compared with individual dietary factors, has long been proposed as a more effective and actionable target for CVD prevention and intervention. 6 Recently, the first randomized controlled trial targeting overall dietary patterns for the primary prevention of CVD, the PREDIMED trial (Prevencion con Dieta Mediterranea), 7 found that the Mediterranean diet (MedDiet) enriched with extra virgin olive oil or nuts significantly reduced CVD events by ≈30% compared with the control diet. 8 On the basis of strong and consistent evidence on hard CVD end points from the PREDIMED trial 8 and prospective cohort studies, [9] [10] [11] [12] the 2015 to 2020 Dietary Guidelines for Americans 13 and the American Heart Association 14 both recommend the MedDiet for CVD prevention. However, the biological mechanisms underlying cardioprotective effects of the MedDiet are not completely understood.
Advances in metabolite profiling technology (metabolomics), especially liquid chromatography tandem mass spectrometry techniques, provide powerful tools to decipher the biological mechanisms of disease. Several structurally different ceramides are among the lipid metabolites profiled by current metabolomics platforms. Recent evidence from 2 small short-term intervention studies found that ceramide concentrations could be transiently decreased by adopting a healthy dietary pattern 15 and changes in primary dietary sources of fat. 16 The MedDiet might also exert its effect through decreasing ceramide concentration. However, it is still largely unknown whether ceramide concentration responds to long-term dietary intervention in a large population. In the present study based on the PREDIMED trial, we hypothesized that (1) plasma ceramide concentrations at baseline were associated with incident clinical events of CVD, (2) the association between baseline plasma ceramide concentrations and incident CVD was modified by the MedDiet interventions, and (3) participants in MedDiet intervention groups showed more favorable changes in plasma ceramide concentration compared with those in the control group during the first year of follow-up.
METHODS Study Design and Population
This study was nested in the PREDIMED randomized trial but adopted a case-cohort design 17, 18 by including all the available incident CVD cases diagnosed during follow-up and randomly sampling 10% of the enrolled participants at baseline in the PREDIMED trial. The case-cohort design preserves random intervention assignments and maintains the causal integrity of the randomized design of the trial. The PREDIMED trial (www. predimed.es) was conducted from 2003 through 2010 in 11 centers in Spain to assess the effects of the MedDiet on the primary prevention of CVD. At baseline, this trial enrolled 7447 participants 55 to 80 years of age with high cardiovascular risk but initially free from diagnosed CVD, including CHD (angina, myocardial infarction, coronary revascularization procedures,
Clinical Perspective
What Is New?
• Our study documented for the first time an association between baseline plasma ceramide concentration and a composite cardiovascular disease outcome defined as nonfatal acute myocardial infarction, nonfatal stroke, or cardiovascular death by using a prospective design nested in a wellknown primary prevention trial, the PREDIMED trial (Prevención con Dieta Mediterránea).
• The traditional Mediterranean diet enriched with extra virgin olive oil or nuts showed the potential to mitigate the deleterious effects of elevated plasma ceramide concentration on cardiovascular disease risk.
What Are the Clinical Implications?
• Our findings shed light on the biological mechanisms underlying cardioprotective effects of the Mediterranean diet, further strengthening the evidence base of recommending the Mediterranean diet for cardiovascular disease prevention.
• The present results suggested that plasma ceramides measured by the liquid chromatography tandem mass spectrometry techniques had the potential to serve as markers of future cardiovascular disease risk in clinical practice.
or existence of abnormal Q waves in the ECG), stroke (ischemic or hemorrhagic, including transient ischemic attacks), and symptomatic peripheral artery disease at baseline. Participants were randomly assigned to a MedDiet supplemented with extra virgin olive oil, a MedDiet supplemented with nuts, or a control diet consisting of advice to reduce the intake of all types of fat. During a mean follow-up time of 4.8 years (maximum follow-up: 7.4 years), 288 incident CVD events occurred. The protocol was approved by the Institutional Review Boards at all study locations, and all participants provided written informed consent. Detailed information about the PREDIMED trial can be found elsewhere. 7, 8 The study population consisted of 980 participants with available ethylenediaminetetraacetic acid plasma samples, including 230 incident cases of CVD and 787 randomly selected participants at baseline (subcohort). The subcohort included 37 overlapping cases of CVD. We excluded 2 participants with undetectable plasma ceramide concentrations.
Study Samples and Metabolomics Profiling
All analyses used fasting (fasting for ≥8 hours) plasma ethylenediaminetetraacetic acid samples collected at baseline and year 1. All samples were processed at each recruiting center ≤2 hours after collection and stored in -80°C freezers. Samples from cases and subcohort participants were randomly distributed before being shipped to the Broad Institute in Boston, Massachusetts, for metabolomics assays. Liquid chromatography tandem mass spectrometry techniques were used to quantitatively profile ceramides in plasma samples. Plasma ceramide metabolites were measured concurrently with other lipid metabolites on the same platform and were identified on the basis of total acyl carbon content and degrees of saturation. Details of the liquid chromatography tandem mass spectrometry platform can be found elsewhere. [19] [20] [21] [22] [23] [24] [25] Internal standard peak areas were monitored for quality control and to ensure system performance throughout analyses. Pooled plasma reference samples were also inserted every 20 samples as an additional quality control.
Ascertainment of CVD Outcomes
The primary outcome was a composite of nonfatal acute myocardial infarction, nonfatal stroke, or cardiovascular death. Information on outcomes was collected from continuous contact with participants and primary healthcare physicians, annual follow-up visits, yearly ad-hoc reviews of medical charts, and annual consultation of the National Death Index. Study physicians who were blinded to the intervention assignment collected information on primary outcomes. The Clinical EndPoint Committee, also blinded to the intervention assignment, adjudicated these events according to published criteria.
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Measurements of Covariates
Medical conditions, family history of disease, and risk factors were collected through a questionnaire during the first screening visit. At baseline and during annual visits, participants completed a 14-item questionnaire in a personal interview with a registered dietitian to assess their adherence to the MedDiet. 32 At baseline and then annually, trained personnel measured participants' body weight, height, waist circumference, and blood pressure according to the study protocol. Body mass index was calculated as weight in kilograms divided by height in meters squared. Participants' triglycerides, total cholesterol, low-density lipoprotein-cholesterol (LDL), high-density lipoprotein-cholesterol (HDL), and fasting blood glucose levels were measured using fasting plasma samples at baseline.
Statistical Analysis
We transformed ceramide concentrations to the natural logarithm scale to render the distributions approximately Gaussian as well as to stabilize the variance. We categorized all the participants into quartiles of the ceramide concentration based on the distribution in the subcohort. Person-years of follow-up were calculated from baseline to the earliest CVD event, loss to follow-up, or the end of follow-up.
Weighted proportional hazards Cox regression models stratified on intervention group assignment (MedDiet+extra virgin olive oil, MedDiet+nuts, and control) were applied to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs) of CVD comparing participants in each quartile to the lowest quartile. We used the weighting scheme suggested by Barlow et al 33, 34 to account for the overrepresentation of cases. To quantify a linear trend, we assigned the median value of ceramide concentration within each quartile and modeled this variable continuously. We also calculated HRs and 95% CIs of CVD associated with a 1-standard deviation (SD) increment in the transformed concentrations of ceramides. All multivariable models were simultaneously adjusted for age, sex, body mass index, family history of premature CHD, smoking status, histories of hypertension, dyslipidemia, and type 2 diabetes mellitus. We adjusted P-values of the multivariable-adjusted associations between 1-SD increment in ceramide concentration and CVD risk using Benjamini-Hochberg procedure to account for the number of other plasma lipid metabolites (n=196) measured concurrently with ceramides on the same subplatform. We calculated a baseline ceramide score as the weighted sum of concentrations of 4 different ceramides and modeled the ceramide score as a main exposure variable in the Cox model in the same fashion as individual ceramides. The weight for each ceramide was the regression coefficient for a 1-SD increment in the ceramide concentration estimated from the multivariable Cox regression model. 19 We also performed secondary analyses on the associations of ceramide concentrations with acute myocardial infarction and stroke separately. Because Laaksonen et al 5 suggested that ratios of ceramides could be stronger predictors of cardiovascular risk than individual ceramides, we also examined these ratios in relation to CVD in a secondary analysis. To test the robustness of our findings, in secondary analyses, the multivariable model was adjusted for the ratio of HDL to LDL (HDL/LDL) and for triglycerides as continuous variables, as well as adjusted for non-HDL as a surrogate for atherogenic lipoproteins, instead of adjusting for dyslipidemia as a dichotomous variable. In addition, we performed several secondary analyses to further adjust for other metabolites putatively associated with CVD that were targeted on the current metabolomics platform. First, we included other sphingolipid metabolites, including sphingomyelins and sphingosine, 35, 36 in the multivariable-adjusted models. Second, we further adjusted for 3 branched-chain amino acids (ie, valine, leucine and isoleucine) because they have been identified as strong predictors of insulin resistance and cardiometabolic risk in our previous study 37 and recent publications. 19, [38] [39] [40] [41] We further explored the associations between the ceramide score and incident CVD risk in subgroups defined by several dichotomous risk factors at baseline, including sex (male, female), age (≤65 years, >65 years), body mass index categories (≤30.0, >30.0 kg/m 2 ), smoking status (never smoking, current/ever smoking), family history of premature CHD (yes, no), hypertension (yes, no), dyslipidemia (yes, no), type 2 diabetes mellitus (yes, no), leisure time physical activity (≤median, >median metabolic equivalent tasks minutes/day), and alcohol consumption (0, 0.1-4.9, ≥5 g/day). The interactions among these stratification variables and the ceramide score were tested by adding multiplicative terms into the multivariable Cox models; the likelihood ratio test was used for testing statistical significance of the interaction term.
In a secondary analysis, we evaluated the added predictive ability of ceramides by comparing the c-statistics between 1 model, including conventional risk factors of CVD (ie, age, sex, systolic blood pressure, total and HDL, current smoking and type 2 diabetes mellitus), and the other model, including ceramide score in addition to the conventional risk factors, as well as estimating the net reclassification improvement 42 for the 7-year risk of CVD. To examine whether the association between plasma ceramide concentration and incident CVD varied by intervention group, we first categorized participants into joint subgroups defined by intervention group assignment and whether their ceramide score was above/equal to or below the median value in the subcohort. Second, we constructed adjusted cumulative incidence curves for the joint subgroups by using the Langholz et al 43 method for case-cohort design and included all the aforementioned covariates in the model. Third, we calculated the multivariable adjusted HRs for CVD from Cox regression models for each joint subgroup using participants with a low ceramide score (below the median) and in the intervention groups as a reference group. Last, we added a multiplicative term between intervention assignment and the ceramide score into the multivariable Cox models stratified on intervention assignment to test for interaction. To compare the temporal changes in ceramide concentrations between intervention and control groups, we used linear mixed model to account for the within-individual repeated measurements and restricted this analysis to the random subcohort. We also explored the associations between baseline characteristics and 1-year changes in ceramide concentration in the subcohort using general linear models that simultaneously included intervention assignments and baseline characteristics. All analyses were performed using SAS software, version 9.4 (SAS Institute) at a 2-tailed α of 0.05.
RESULTS
Baseline Characteristics
The median follow-up of the analytic population was 4.5 years. The baseline characteristics of the subcohort were similar to those of the full cohort in the PREDIMED trial, 8 except for a slightly higher proportion of participants with a family history of premature CHD (Table 1) . At baseline, participants with a higher ceramide score had higher levels of total cholesterol, LDL, triglycerides, and diastolic blood pressure.
Plasma Ceramide Concentrations and CVD
The current metabolomics platform identified 4 different ceramides, including ceramide (d18:1/16:0), ceramide (d18:1/22:0), ceramide (d18:1/24:0), and ceramide (d18:1/24:1). For short, we labeled the 4 ceramides as C16:0 (number of carbon atoms:number of double bonds in the fatty acid chain), C22:0, C24:0, and C24:1, respectively. Ceramide C24:0 had the highest relative concentration, whereas ceramide C16:0 had the lowest relative concentration (Table I in the online-only Data Supplement). We observed moderate and positive correlations in plasma concentrations among the 4 ceramides, ranging from 0.49 to 0.63, except for a high correlation of 0.90 between ceramides C22:0 and C24:0 (Table II in the onlineonly Data Supplement). All the ceramides were positively associated with incident CVD risk; the positive associations only differed in magnitude across different ceramide species and became slightly stronger after multivariable adjustment ( Table 2 ). The multivariable HRs comparing the extreme quartiles of plasma concentrations of C16:0, C22:0, C24:0, and C24:1 ceramides were 2.39 (95% CI, 1.49-3.83; P for trend <0.001), 1.91 (95% CI, 1.21-3.01; P for trend =0.003), 1.97 (95% CI, 1.21-3.20; P for trend =0.004), and 1.73 (95% CI, 1.09-2.74; P for trend =0.011), respectively. The P-values for the associations between a 1-SD increment in ceramide concentration and CVD risk after multiple comparison adjustment were 0.007, 0.045, 0.050, and 0.050 for ceramides C16:0, C22:0, C24:0, and C24:1, respectively. The ceramide score was associated with a 2.18-fold higher risk of CVD across quartiles (HR, 2.18; 95% CI, 1.36-3.49; P for trend <0.001). The HR associated with a 1-SD increment in the ceramide score was 1.41 (95% CI, 1.17-1.68). The associations of ceramides and the ceramide score with CVD risk barely changed after further adjustment for sphingomyelins, sphingosine, and branched-chain amino acids, and they were slightly attenuated in models adjusting for HDL/LDL ratio and triglycerides and for non-HDL as continuous variables (Table III in the online-only Data Supplement). Secondary analyses on stroke and acute myocardial infarction yielded similar associations between plasma ceramides and the specific CVD outcomes, compared with the main analysis of the composite CVD outcome (Table IV in the online-only Data Supplement). The associations between ceramide score and CVD risk were generally consistent across different risk strata subgroups defined by gender, age, body mass index, smoking status, family history of CHD, baseline histories of type 2 diabetes mellitus, dyslipidemia, hypertension, alcohol consumption, and leisure time physical activity (Table V in 
Interactions Between Plasma Ceramide Concentrations and the MedDiet Interventions
Figure shows that the association between baseline ceramide score and the incidence of CVD clinical events varied significantly by intervention group assignment. Using the median ceramide score as the cut point, participants with a higher ceramide score and randomized to either of the 2 active arms of the trial showed similar incidence of CVD to those with a lower ceramide score. However, the cumulative incidence curve for participants with a higher ceramide score and randomized to the control group diverged from those in other subgroups soon after the initiation of this trial. Compared with participants with a lower ceramide score and randomized to either of the 2 active intervention arms of the trial, the HRs were 2.76 (95% CI, 1.72-4.44) for participants with a higher ceramide score and randomized to the control group, 1.07 (95% CI, 0.64-1.78) HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; and Q, quartile. *The subcohort also included 37 cases. †Adherence to the Mediterranean diet was assessed using a 14-item dietary screener. ‡Quartiles were calculated on the basis of the distribution of the ceramide score (weighted sum of 4 ceramides) in the subcohort. §To quantify a linear trend, we assigned the median within each quartile and modeled this scored trend variable continuously; Wald test was used for calculating P for trend. Logistic model was used for categorical variable, and general linear model was used for continuous variable.
for those with a lower ceramide score and randomized to the control group, and 1.26 (95% CI, 0.84-1.87) for those with a higher ceramide score and randomized to either of the 2 active intervention arms (P for interaction =0.010; Table VII in the online-only Data Supplement). The association between the baseline ceramide score and incident CVD also varied significantly when the 2 intervention groups were examined separately (Figure) . The interaction between the MedDiet+extra virgin olive oil intervention and the ceramide score was more pronounced (P for interaction =0.009) than that between the MedDiet+nuts intervention and the ceramide score (P for interaction =0.053).
Changes in Ceramide Concentration
One-year changes in ceramide concentration were not significantly different between participants in either of the 2 intervention groups and those in the control group (Table VIII in the online-only Data Supplement). We observed similar trends in ceramide concentrations when comparing each MedDiet group to the control group. In addition, none of the baseline characteristics was significantly associated with 1-year changes in ceramide concentration (Table IX in 
DISCUSSION
In this prospective case-cohort study within the PRE-DIMED trial, we observed that plasma ceramide concentrations were independently associated with elevated risk of the composite CVD outcome defined as nonfatal acute myocardial infarction, nonfatal stroke, or cardiovascular death, which was the primary end point of the PREDIMED trial. The positive association was consistent for 2 major components of the composite CVD end point, namely, acute myocardial infarction and stroke, and across differ- Values in parentheses are hazard ratios of incident cardiovascular disease (95% confidence interval). MV indicates multivariable model; and Q, quartile.
*Quartiles were calculated on the basis of the distribution of the ceramide concentrations in the subcohort. †A logarithmic transformation was applied to the raw value. ‡Model 1 was stratified on intervention group and simultaneously adjusted for age (continuous) and sex (male, female). §Model 2 was also adjusted for body mass index (kg/m 2 , continuous), family history of premature coronary heart disease (yes, no), smoking status (current, never, former), histories of hypertension, dyslipidemia, and type 2 diabetes mellitus (all yes, no).
Figure. Adjusted cumulative incidence curves in joint subgroups defined by ceramide score and intervention group assignment.
A, Adjusted cumulative incidence curves in the following joint subgroups: participants with a ceramide score ≥median and randomized to either of the 2 Mediterranean diet intervention arms, participants with a ceramide score <median and randomized to either of the 2 Mediterranean diet intervention arms, participants with a ceramide score ≥median and randomized to the control arm, and participants with a ceramide score <median and randomized to the control arm. B, Adjusted cumulative incidence curves in the following joint subgroups: participants with a ceramide score ≥median and randomized to the intervention arm with Mediterranean diet+extra virgin olive oil, participants with a ceramide score <median and randomized to the intervention arm with Mediterranean diet+extra virgin olive oil, participants with a ceramide score ≥median and randomized to the control arm, and participants with a ceramide score <median and randomized to the control arm. (Continued ) ent subgroups defined by baseline risk characteristics. In addition, the association between plasma ceramides and CVD risk varied significantly across intervention groups, suggesting that the MedDiet may have the potential to mitigate the detrimental effect associated with elevated baseline plasma ceramide concentrations on CVD risk.
This study, to our knowledge, is the first prospective study in a clinical trial setting to investigate the association between plasma ceramide concentrations and hard CVD end points. Previously, in vitro and in vivo animal studies have provided substantial evidence relating ceramide accumulation to multiple mechanisms underlying pathogenesis of CVD. However, human data are still sparse and limited by their small sample size and cross-sectional study design. The role of ceramides in the development of insulin resistance has been intensively studied in the past 2 decades. Earlier studies using cultured cells and animal models suggested that endogenous ceramides antagonized insulin-stimulated glucose uptake and anabolism 44, 45 by blocking activation of Akt/PKB, a serine/ threonine kinase that is obligate for insulin and growthfactor activation of anabolism and cell survival. [46] [47] [48] [49] [50] [51] Human studies reported increased ceramide concentration in obese insulin-resistant participants 52 and a negative correlation between muscle and plasma ceramide and insulin sensitivity. [53] [54] [55] Interestingly, our data did not support cross-sectional associations between ceramide concentrations and several baseline characteristics related to insulin resistance (eg, body mass index, prevalence of type 2 diabetes mellitus, and fasting glucose). It is possible that these associations were diluted among this study population given that all our participants were selected because they were high-risk subjects and most of them might have already developed insulin resistance at the time of the enrollment. Beyond insulin resistance, limited human studies have observed positive correlations between plasma ceramide concentrations and inflammatory makers (eg, interleukin-6 56 and tumor necrosis factor-α), 57 suggesting a relationship between excess ceramides and inflammation. Several lines of evidence in rodent models suggest that pharmacological inhibition of ceramide biosynthesis prevents atherogenesis. 58, 59 Ceramides and other sphingolipids may contribute to plaque erosion and therefore induce thrombosis. 3 Of note, these studies on plaque formation 58, 59 also found that inhibition of ceramide biosynthesis caused a reduction of circulating total cholesterol and LDL, which is consistent with our cross-sectional observations on ceramide concentrations and blood lipid profiles. Elevated ceramides were also implicated in cardiomyopathy. For example, Park et al 60 observed that inhibition of a rate-limiting enzyme in ceramide biosynthesis (serine palmitoyltransferase) imFigure Continued. C, Adjusted cumulative incidence curves in the following joint subgroups: participants with a ceramide score ≥median and randomized to the intervention arm with Mediterranean diet+nuts, participants with a ceramide score <median and randomized to the intervention arm with Mediterranean diet+nuts, participants with a ceramide score ≥median and randomized to the control arm, and participants with a ceramide score <median and randomized to the control arm. Cumulative incidence curves were adjusted for age (continuous) and sex (male, female), body mass index (kg/m 2 , continuous), family history of premature coronary heart disease (yes, no), smoking status (current, never, former), histories of hypertension, dyslipidemia, and type 2 diabetes mellitus (all yes, no). CI indicates confidence interval; EVOO, extra virgin olive oil; and MedDiet, Mediterranean diet.
proved systolic function and prolonged survival rates in a mouse model. Laaksonen et al 5 observed an elevated risk of CVD death in patients with CHD with higher plasma concentration of 3 ceramide species (C16:0, C18:0, and C24:1) but a nonsignificantly lower risk of CVD death in those with higher concentration of ceramide C24:0. However, we found that all 4 ceramides were positively associated with the incidence of CVD. Further, the ratios of ceramides did not show stronger associations with CVD risk than individual ceramides or the summary ceramide score. The evidence regarding whether distinct ceramide metabolites were divergently associated with insulin resistance was also inconsistent. [61] [62] [63] Further studies are warranted to investigate the potential different biological effects of ceramides with different acyl-chain length.
We observed that the detrimental effect of higher ceramide concentrations on CVD risk was modified by the MedDiet intervention. The potential mechanisms for the MedDiet's modulatory effects on the ceramide pathway are 2-fold. First, consumption of key components of the MedDiet may directly influence ceramide biosynthesis. Studies using cultured myotubes and animal models found that exposure to saturated FFAs, especially longchain saturated FFAs, promoted ceramide formation, 64, 65 whereas unsaturated FFAs prevented the excess ceramide accumulation stimulated by saturated FFAs, 66 and therefore postulated that the rate-limiting serine palmitoyltransferase was specific to the composition of circulating FFAs. 3 The PREDIMED trial was effective in modifying intervention groups' dietary patterns, 8 which were characterized by a high intake of extra virgin olive oil, fruit, nuts, vegetables, and cereals; a moderate intake of fish and poultry; a low intake of dairy products, red meat, processed meats, and sweets; and wine in moderation, consumed with meals. 67 In conjunction with 2 supplemental foods, extra virgin olive oil and nuts, the interventions might have changed circulating FFA composition through modifying dietary fat intake pattern (ie, decreasing saturated fat intake and increasing monounsaturated and polyunsaturated fat intakes) and modulating de novo lipogenesis on improvement in dietary carbohydrate quality. It is worth noting that our analysis did not find that the MedDiet was associated with favorable changes in ceramide concentrations during the first year of follow-up. However, we cannot rule out that the MedDiet may directly mitigate aberrant ceramide accumulation in longer follow-up. Second, the MedDiet intervention could suppress deleterious effects after excess ceramide accumulation. Previous studies have suggested that the benefits of the MedDiet pattern on CVD could be mediated through several mechanisms, including the reduction of low-grade inflammation, [68] [69] [70] [71] [72] enhanced endothelial function, 70, 73, 74 lower oxidative stress, 75, 76 and lower levels of oxidized LDL 77 and atherogenic lipoproteins. 78 Our results should be interpreted in the context of several limitations. First, participants of this project were mostly European whites, which might limit the generalizability of our findings to other populations. Second, participants were recruited based on their high CVD risk. Therefore, our findings might not be applicable in populations with low CVD risk. Third, after adjusting for multiple comparisons, several of the P-values were of borderline statistical significance. However, the consistency of these results across the plasma ceramides supports the robustness of these observations. Although we carefully adjusted for many potential confounders, residual confounding cannot be ruled out.
Our study possesses several major strengths. First, this study was built on a large, successful randomized controlled trial of hard clinical CVD end points, which provided a unique and powerful setting to address our research questions because of its well-characterized study population, high compliance to the interventions, and low rates of dropout. Second, the case-cohort design preserved the randomized design of this intervention trial and maintained the causal integrity of a randomized exposure status.
In summary, our study documented for the first time a strong positive association between plasma ceramide concentrations and incident CVD risk by using a prospective design nested in a well-known randomized trial. In addition, the traditional MedDiet intervention showed the potential to mitigate deleterious effects on CVD risk related to elevated plasma ceramide concentrations. Further studies are warranted to replicate these results in other populations and investigate potential mechanisms.
